Imatinib mesylate.pptVIP

Discovery of Imatinib mesylate Imatinib mesylate 甲磺酸伊马替尼 Commercial name : Gleevec 格列卫 Invented by Novartis pharmaceutical limited 　由诺华制药有限公司研发 For the treatment of chronic myelogenous leukemia 　用于治疗慢性粒细胞白血病 Mechanism It is a selective tyrosine kinase inhibitor（酪氨酸激酶抑制剂） . The tyrosine kinase BCR-ABL ,only found in leukemic cells ,is the target（靶点）chosen by Zimmerman and the Novartis group. Inhibiting this target reduces toxicity and maximizes the desired therapeutic effect（减毒增效）. Process of discovery Advantages of a defined target An oncogene（癌基因） inhibitor should be selectively toxic to